YN001治疗成人冠状动脉粥样硬化的2b期临床试验 (PURIFY-TIMI 81)
一项随机、多中心、双盲、平行、安慰剂对照的2b期临床试验,旨在评估YN001在成年冠状动脉粥样硬化患者中的疗效和安全性
This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.
研究概览
详细说明
This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.
A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Jingmei Zhang, Master
- 电话号码:0086 010 82599080
- 邮箱:zhangjingmei@innovmedicine.com
研究联系人备份
- 姓名:Kaiqi Zong, Master
- 电话号码:0086 010 82599080
- 邮箱:zongkaiqi@innovmedicine.com
学习地点
-
-
An
-
Hefei、An、中国、230022
- 招聘中
- The First Affiliated Hospital of Anhui Medical Unversity
-
接触:
- Jianlong Wang, MD
- 电话号码:0086-13681292304
- 邮箱:Wjlmll@sina.com
-
-
Anhui
-
Hefei、Anhui、中国、230001
- 招聘中
- Anhui Provincial Hospital
-
接触:
- Kangyu Chen, MD
- 电话号码:0086 18056005099
- 邮箱:ustccky@126.com
-
首席研究员:
- Kangyu Chen, MD
-
副研究员:
- Chao Gao, MD
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100035
- 招聘中
- Beijing Jishuitan Hospital
-
首席研究员:
- Wei Liu, MD
-
接触:
- Qingwei Ji, MD
- 电话号码:0086 18376642655
- 邮箱:jqwl24@163.cou
-
首席研究员:
- Qingwei Ji, MD
-
Beijing、Beijing Municipality、中国、100029
- 招聘中
- Anzhen Hospital
-
接触:
- Yuyang Liu, MD
- 电话号码:0086 010-64456488
- 邮箱:liuyy803803@163.com
-
首席研究员:
- Yuyang Liu, MD
-
Beijing、Beijing Municipality、中国、101100
- 尚未招聘
- Beijing Luhe Hospital
-
接触:
- Guangyao Zhai, MD
- 电话号码:+86 1069543901
- 邮箱:drzhaiguangyao@163.com
-
-
Fujian
-
Fuzhou、Fujian、中国、350001
- 招聘中
- Fujian Medical University Union Hospital
-
接触:
- Mingfang Ye, MD
- 电话号码:0086 13960818759
- 邮箱:xieheyemingfang@163.com
-
首席研究员:
- Mingfang Ye, MD
-
副研究员:
- Zhaoyang Chen, MD
-
-
Gansu
-
Lanzhou、Gansu、中国、730030
- 招聘中
- The Second Hospital & Clinical Medical School Lanzhou University
-
接触:
- Feng Bai, MD
- 电话号码:0086-13609363049
- 邮箱:baifeng@medmail.com.cn
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510080
- 招聘中
- Guangdong Provincial People's Hospital
-
接触:
- Ning Tan, MD
- 邮箱:tanning100@126.com
-
接触:
- 电话号码:0086-13903073651
- 邮箱:tangning100@126.com
-
-
Heilongjiang
-
Daqing、Heilongjiang、中国、163316
- 招聘中
- Daqing People's Hospital
-
接触:
- Shu Zhang
- 电话号码:+86-459-6612898
- 邮箱:dqsrmyygcp@163.com
-
Harbin、Heilongjiang、中国、150001
- 招聘中
- The First Affiliated Hospital of Harbin Medical University
-
接触:
- Lu Fu, MD
- 电话号码:0086 137 9668 4968
- 邮箱:fuluyidayi@163.com
-
首席研究员:
- Lu Fu, MD
-
首席研究员:
- Yongtai Gong, MD
-
-
Hubei
-
Wuhan、Hubei、中国、430071
- 招聘中
- Zhongnan Hospital of Wuhan University
-
接触:
- Xiaorong Hu, MD
- 电话号码:0086 15927681634
- 邮箱:huzrzn@whu.edu.cn
-
首席研究员:
- Xiaorong Hu, MD
-
-
Hunan
-
Changsha、Hunan、中国、410008
- 招聘中
- The Second Xiangya Hospital fo Central South University
-
接触:
- Xinqun Hu, MD
- 电话号码:0086-13307313627
- 邮箱:huxinqungs@163.com
-
-
Jilin
-
Changchun、Jilin、中国、130033
- 招聘中
- The First Hospital of Jilin University
-
首席研究员:
- Qian Tong, MD
-
接触:
- Qian Tong, MD
- 电话号码:0086 13074337289
- 邮箱:tongqian187@aliyun.com
-
-
Liaoning
-
Shenyang、Liaoning、中国、110015
- 招聘中
- The People's Hospital of Liaoning Province
-
首席研究员:
- Ying Liu, MD
-
接触:
- Ying Liu, MD
- 电话号码:0086 13840065379
- 邮箱:liuyingwangli@126.com
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710068
- 招聘中
- Shaanxi Provincial People's Hospital
-
接触:
- Xiling Shou, MD
- 电话号码:0086 18966700335
- 邮箱:shouxiling@163.com
-
-
Shandong
-
Jinan、Shandong、中国
- 招聘中
- Central Hospital Affiliated to Shandong First Medicial University
-
接触:
- Guohai Su, MD
- 电话号码:0086 19953193319
- 邮箱:gttstg@163.com
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- 招聘中
- Fudan University-Zhongshan Hospital
-
首席研究员:
- Junbo Ge, MD
-
接触:
- Junbo Ge, MD
- 电话号码:021-64041990
- 邮箱:ge.junbo@zs-hospital.sh.cn
-
副研究员:
- Yuxiang Dai, MD
-
Shanghai、Shanghai Municipality、中国、200001
- 招聘中
- Renji Hospital Shanghai Jiaotong University school of medicine
-
接触:
- Jun Bu, MD
- 电话号码:0086 13601958108
- 邮箱:pujun310@hotmail.com
-
首席研究员:
- Jun Bu, MD
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- 招聘中
- West China Hospital of Sichuan University
-
接触:
- Yong He, MD
- 电话号码:0086 18980602038
- 邮箱:zznnyeah@163.com
-
首席研究员:
- Yong He, MD
-
Chengdu、Sichuan、中国、610072
- 招聘中
- Sichuan Provincial People's Hospital
-
接触:
- Jianhong Tao, DM
- 电话号码:86-189 8183 8875
- 邮箱:Taojianhong06@medmail.com.cn
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300211
- 招聘中
- The Second Hospital of Tianjin Medical University
-
接触:
- Tong Liu, MD
- 电话号码:0086 13902183163
- 邮箱:liutongdoc@126.com
-
首席研究员:
- Tong Liu, MD
-
Tianjin、Tianjin Municipality、中国、300121
- 招聘中
- Tianjin People's Hospital
-
首席研究员:
- Zhuhua Yao, MD
-
接触:
- Zhuhua Yao, MD
- 电话号码:0086 13902199877
- 邮箱:tjyzhpci@163.com
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310006
- 招聘中
- Zhejiang Provincial People's Hospital
-
接触:
- Lihong Wang, MD
- 电话号码:0086-13666690598
- 邮箱:wlhhz@hotmail.com
-
Suzhou、Zhejiang、中国、215006
- 招聘中
- The First Affiliated Hospital of Soochow University
-
接触:
- Tingbo Jiang, MD
- 电话号码:0086-18906201122
- 邮箱:jiangtingbo6797@163.com
-
Wenzhou、Zhejiang、中国、325000
- 招聘中
- The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
-
接触:
- lianpin Wu, MD
- 邮箱:198019@wzhealth.com
-
-
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大、R2H 2A6
- 尚未招聘
- St. Boniface Hospital
-
接触:
- Shuangbo Liu
- 电话号码:204-237-2793
- 邮箱:sliu@sbgh.mb.ca
-
-
Ontario
-
London、Ontario、加拿大、N5A 5A5
- 尚未招聘
- London Health Sciences Centre
-
接触:
- Habib Khan
- 电话号码:519-663-3197
- 邮箱:habib.khan@lhsc.on.ca
-
North York、Ontario、加拿大、M6B 3H7
- 尚未招聘
- North York Diagnostic and Cardiac Centre
-
接触:
- Subodh Verma, MD
- 电话号码:416-436-0244
- 邮箱:subodh.verma@unityhealth.to
-
Toronto、Ontario、加拿大、M5B 1W8
- 尚未招聘
- St. Michael's Hospital
-
接触:
- John Graham
- 电话号码:416-864-6060
- 邮箱:John.Graham@unityhealth.to
-
Vaughan、Ontario、加拿大、L6A 4N9
- 尚未招聘
- Cardiac Clinic
-
接触:
- Navneet Singh
- 电话号码:905-417-3001
- 邮箱:navneet.singh@thp.ca
-
-
Toronto
-
Toronto、Toronto、加拿大、M5G 2N2
- 尚未招聘
- Toronto General Hospital - University Health Network
-
接触:
- Jacob Udell
- 电话号码:416-340-4800
- 邮箱:jay.udell@utoronto.ca
-
-
-
-
New South Wales
-
Penrith、New South Wales、澳大利亚、2750
- 招聘中
- Cannopy Clinical Research
-
接触:
- Karen Kaluhin, MD
- 电话号码:0061 0491 276 512
- 邮箱:kkaluhin@canopycr.com.au
-
-
Queensland
-
Brisbane、Queensland、澳大利亚、4064
- 招聘中
- Core Research Group Pty Ltd.
-
接触:
- David Colquhou, MD
- 电话号码:614-1184-2788
- 邮箱:d.colquhoun@uq.edu.au
-
-
Victoria
-
Altona N.、Victoria、澳大利亚、3025
- 招聘中
- Canopy Clinical Research
-
接触:
- Oscar Walsh, MD
- 电话号码:0061 03 9968 7601
- 邮箱:owalsh@canopycr.com.au
-
-
-
-
Alabama
-
Huntsville、Alabama、美国、35801-4312
- 招聘中
- Heart Center Research, LLC
-
接触:
- Walter Haught, MD
- 电话号码:256-519-8472
- 邮箱:hhaught@theheartcenter.md
-
-
California
-
Covina、California、美国、91740
- 尚未招聘
- Thrive Clinical Research Group, LLC
-
接触:
- Sami Hayek
- 电话号码:818-280-4220
- 邮箱:samihayek82@hotmail.com
-
Lincoln、California、美国、95648
- 尚未招聘
- Clinical Trials Research
-
接触:
- Jeffrey Wayne, MD
- 电话号码:916-434-8230
- 邮箱:jwaynemd@ctrsites.com
-
Los Alamitos、California、美国、90720
- 尚未招聘
- University of California Irvine Medical Center - Cardiovascular Center
-
接触:
- Arnold Seto
- 电话号码:562-598-3200
- 邮箱:arnold.seto@va.gov
-
Stanford、California、美国、94305-2200
- 尚未招聘
- Stanford Health Care General Cardiology
-
接触:
- Fahim Abbasi, MD
- 电话号码:650-723-6459
- 邮箱:fahim@stanford.edu
-
Torrance、California、美国、90502-2006
- 招聘中
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
接触:
- Matthew Budoff, MD
- 电话号码:310-222-3641
- 邮箱:mbudoff@lundquist.org
-
-
Florida
-
Boca Raton、Florida、美国、33434
- 尚未招聘
- Flourish Research - Boca Raton
-
接触:
- Richard Goldman
- 电话号码:561-756-8206
- 邮箱:rgoldman@flourishresearch.com
-
Hialeah、Florida、美国、33016-1895
- 招聘中
- New Generation of Medical Research, LLC.
-
接触:
- Karelia Ruiz
- 电话号码:305-828-9100
- 邮箱:kareliar@ngmresearch.com
-
St. Petersburg、Florida、美国、33709
- 招聘中
- HCA Florida Heart Institute
-
接触:
- Robert Sanchez, MD
- 电话号码:727-490-2100
- 邮箱:robert.sanchez7@hcahealthcare.com
-
-
Georgia
-
Atlanta、Georgia、美国、30303-3049
- 尚未招聘
- Emory Healthcare-Emory Heart & Vascular Center - Executive Park
-
接触:
- Modele Ogunniyi
- 电话号码:404-616-4440
- 邮箱:modele.ogunniyi@emory.edu
-
-
Idaho
-
Meridian、Idaho、美国、83642
- 尚未招聘
- St. Luke's Clinic - Idaho Cardiology Associates
-
接触:
- Brian Nolan
- 电话号码:208-322-1680
- 邮箱:bnolan@slhs.org
-
-
Illinois
-
Springfield、Illinois、美国、62781
- 尚未招聘
- Southern Illinois University School of Medicine
-
接触:
- Abdul Hafiz, MD
- 电话号码:217-545-8000
- 邮箱:ahafiz96@siumed.edu
-
-
Kansas
-
Overland Park、Kansas、美国、66211-1215
- 招聘中
- Midwest Heart & Vascular Specialists, LLC
-
接触:
- Stephen Bloom, MD
- 电话号码:913-253-3000
- 邮箱:sbloom@kc.rr.com
-
-
Missouri
-
St Louis、Missouri、美国、63110-1032
- 招聘中
- WU School of Medicine - (CAM) - Heart and Vascular Center
-
接触:
- Farhan Katchi, MD
- 电话号码:314-362-1291
- 邮箱:katchif@wustl.edu
-
-
North Carolina
-
Raleigh、North Carolina、美国、27607
- 尚未招聘
- NC Heart and Vascular Research, LLC
-
接触:
- Mohit Pasi
- 电话号码:919-784-2300
- 邮箱:mohit.pasi2@unchealth.unc.edu
-
Winston-Salem、North Carolina、美国、27104-3520
- 尚未招聘
- Javara Inc. - Wake Forest University Health Sciences
-
接触:
- Michael Shapiro, MD
- 电话号码:336-713-7251
- 邮箱:owen.spitz@javararesearch.com
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- 尚未招聘
- The Christ Hospital
-
接触:
- Mark Berlacher, MD
- 电话号码:513-585-1777
- 邮箱:Mark.Berlacher@thechristhospital.com
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73135
- 尚未招聘
- South Oklahoma Heart Research, LLC
-
接触:
- Naeem Tahirkheli
- 电话号码:405-628-6865
- 邮箱:ntahirkheli@okheart.com
-
-
Pennsylvania
-
Camp Hill、Pennsylvania、美国、17011
- 招聘中
- Capital Area Research, LLC - Camp Hill
-
接触:
- Venkatesh Nadar, MD
- 电话号码:717-695-8722
- 邮箱:VNadar@care-research.com
-
-
Texas
-
Amarillo、Texas、美国、79106
- 招聘中
- PharmaTex Research, LLC
-
接触:
- David Brabham
- 电话号码:806-355-2581
- 邮箱:dgbrabham@hotmail.com
-
Carrollton、Texas、美国、75010
- 尚未招聘
- Pulse Care Heart and Vascular
-
接触:
- Kiran Kumar Mangalpally
- 电话号码:214-407-8640
- 邮箱:trials@stryderesearch.com
-
Tomball、Texas、美国、77375
- 尚未招聘
- DM Clinical Research - Dallas
-
接触:
- Mustafa Mandviwala
- 电话号码:346-550-9559
- 邮箱:drmandviwala.ns@dmclinical.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
- Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
- Participants must satisfy either of the following criteria:
1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:
-
A history of Type 2 diabetes requiring treatment with medication,
-
Aged > 55 years (women) or > 50 years (men),
-
2 or more of the following atherosclerosis risk factors:
-
Current cigarette smoker
-
Hypertension
-
Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2
4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.
5. Female participants must be non-pregnant and non-lactating
6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.
-
Exclusion Criteria:
- Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
- Previously received YN001.
- Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
- Contraindication for CCTA
- 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
- Acute MI that occurred within 4 weeks prior to randomization.
- PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
- Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
- Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
- Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
- New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
- Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
- History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
- History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
- Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
- Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
- Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
- Presence of any type of autoimmune disease.
- Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
- Life expectancy is less than 1 year.
- Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
- Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
- LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
- Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
- Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
- Untreated or inadequately treated hypothyroidism.
- Poorly controlled Type 2 diabetes mellitus.
- A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
- Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dose 1 YN001/Placebo 40mg
Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly |
Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
实验性的:Dose 2 YN001/Placebo 20mg
Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly |
YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
|
安慰剂比较:Dose 3 YN001/Placebo 0mg
Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly |
YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Relative change from baseline in coronary NCPV at Week 13
大体时间:Baseline to Week 13
|
Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA) |
Baseline to Week 13
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
大体时间:From baseline to Week 13
|
Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound. |
From baseline to Week 13
|
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
大体时间:From baseline to Week 9
|
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9 |
From baseline to Week 9
|
|
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
大体时间:From baseline to Week 13
|
Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound |
From baseline to Week 13
|
|
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
大体时间:From baseline to Week 9 and Week 13
|
Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound |
From baseline to Week 9 and Week 13
|
|
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
大体时间:From baseline to Week 13
|
Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA |
From baseline to Week 13
|
|
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
大体时间:From baseline to week 13
|
Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA. |
From baseline to week 13
|
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
大体时间:From baseline to week 48
|
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA |
From baseline to week 48
|
|
Absolute change in coronary NCPV at week 13 and week 48
大体时间:From baseline to week 13 and week 48
|
Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA |
From baseline to week 13 and week 48
|
|
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
大体时间:From randomization to Week 96
|
Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina |
From randomization to Week 96
|
|
The safety profile of YN001
大体时间:From baseline to Week 13
|
Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI) |
From baseline to Week 13
|
|
Immunogenicity (ADA) analysis
大体时间:From baseline to Week 13
|
Incidence of anti-drug antibodies (ADA) formation |
From baseline to Week 13
|
|
Immunogenicity (APA) analysis
大体时间:From baseline to Week 17
|
Incidence of anti-PEG antibodies (APA) formation |
From baseline to Week 17
|
|
YN001 concentrations analysis in plasma
大体时间:From baseline to Week 13
|
Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models |
From baseline to Week 13
|
合作者和调查者
调查人员
- 研究主任:Ying Chen, PhD、Beijing Inno Medicine Co., Ltd.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.